Patents by Inventor Stewart Abbot

Stewart Abbot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10967005
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Publication number: 20210032596
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: March 12, 2020
    Publication date: February 4, 2021
    Applicant: Celularity, Inc.
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20200407681
    Abstract: Provided herein are methods in the field of cell culture, specifically of culture and expansion of immune cells, e.g., T lymphocytes.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 31, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Willard Foss, Thomas Daniel
  • Patent number: 10329529
    Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 25, 2019
    Assignee: CELULARITY, INC.
    Inventors: Stewart Abbot, Kathy Karasiewicz-Mendez, Xiaokui Zhang
  • Publication number: 20190175652
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: February 14, 2019
    Publication date: June 13, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Publication number: 20190117692
    Abstract: Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.
    Type: Application
    Filed: August 22, 2018
    Publication date: April 25, 2019
    Inventors: Stephen M. G. Gottschalk, Xiao-Tong Song, Kota Iwahori, Mireya Paulina Velasquez, Stewart Abbot
  • Publication number: 20190119399
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Application
    Filed: October 30, 2018
    Publication date: April 25, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • Patent number: 10238690
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 26, 2019
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Patent number: 10150816
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: December 11, 2018
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • Publication number: 20180273640
    Abstract: Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Bitao Liang, Stewart Abbot, Wei Liu
  • Patent number: 10041043
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 7, 2018
    Assignee: CELULARITY, INC.
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20180071343
    Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 15, 2018
    Applicant: Celularity, Inc.
    Inventors: Stewart Abbot, James Edinger, Aleksander Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
  • Patent number: 9763983
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 19, 2017
    Assignee: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
  • Publication number: 20170240860
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: October 28, 2015
    Publication date: August 24, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20170000828
    Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 5, 2017
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20160362659
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 15, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20160361366
    Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.
    Type: Application
    Filed: October 22, 2015
    Publication date: December 15, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
  • Publication number: 20160137980
    Abstract: Provided herein are methods in the field of cell culture, specifically of culture and expansion of immune cells, e.g., T lymphocytes.
    Type: Application
    Filed: June 23, 2014
    Publication date: May 19, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, Willard Foss, Thomas Daniel
  • Publication number: 20160106784
    Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
  • Patent number: 9255248
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 9, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang